De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Aarti Drugs Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Aarti Drugs has been growing earnings at an average annual rate of 1.9%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 9.4% per year. Aarti Drugs's return on equity is 12.2%, and it has net margins of 6.5%.
Belangrijke informatie
1.9%
Groei van de winst
2.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 9.4% |
| Rendement op eigen vermogen | 12.2% |
| Nettomarge | 6.5% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Sep 20
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet
Sep 05Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?
May 04Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models
Feb 01Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00
Jan 30Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think
May 17These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well
Nov 22We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet
Aug 28Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching
Aug 19Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value
May 17Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock
Apr 04Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?
Mar 17Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?
Feb 17Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio
Feb 04
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?
Jan 22Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth
Jan 07If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late
Dec 23Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly
Dec 08Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 23How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?
Nov 08Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)
Oct 11Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 514% Share Price Increase Shows How Capitalism Can Build Wealth
Sep 23Aarti Drugs Limited's (NSE:AARTIDRUGS) Business Is Trailing The Market But Its Shares Aren't
Sep 10Opbrengsten en kosten
Hoe Aarti Drugs geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 24,228 | 1,568 | 1,033 | 0 |
| 31 Mar 24 | 25,286 | 1,714 | 1,047 | 0 |
| 31 Dec 23 | 26,510 | 1,802 | 1,032 | 0 |
| 30 Sep 23 | 27,090 | 1,802 | 1,013 | 0 |
| 30 Jun 23 | 27,552 | 1,794 | 967 | 0 |
| 31 Mar 23 | 27,161 | 1,663 | 933 | 0 |
| 31 Dec 22 | 26,679 | 1,656 | 895 | 0 |
| 30 Sep 22 | 26,387 | 1,872 | 867 | 0 |
| 30 Jun 22 | 25,306 | 1,910 | 853 | 0 |
| 31 Mar 22 | 24,886 | 2,050 | 841 | 0 |
| 31 Dec 21 | 22,961 | 2,014 | 822 | 0 |
| 30 Sep 21 | 21,916 | 2,111 | 812 | 0 |
| 30 Jun 21 | 21,901 | 2,438 | 817 | 0 |
| 31 Mar 21 | 21,548 | 2,804 | 815 | 0 |
| 31 Dec 20 | 21,027 | 2,876 | 808 | 0 |
| 30 Sep 20 | 20,459 | 2,474 | 783 | 0 |
| 30 Jun 20 | 19,453 | 2,044 | 717 | 0 |
| 31 Mar 20 | 18,061 | 1,414 | 710 | 0 |
| 31 Dec 19 | 18,156 | 1,100 | 728 | 0 |
| 30 Sep 19 | 17,222 | 1,031 | 703 | 0 |
| 30 Jun 19 | 15,921 | 888 | 679 | 0 |
| 31 Mar 19 | 15,609 | 898 | 665 | 0 |
| 31 Dec 18 | 14,136 | 863 | 634 | 0 |
| 30 Sep 18 | 13,689 | 887 | 635 | 0 |
| 30 Jun 18 | 13,407 | 943 | 630 | 0 |
| 31 Mar 18 | 12,436 | 823 | 618 | 0 |
| 31 Dec 17 | 11,592 | 790 | 613 | 0 |
| 30 Sep 17 | 11,340 | 735 | 590 | 0 |
| 30 Jun 17 | 11,569 | 721 | 580 | 0 |
| 31 Mar 17 | 11,952 | 818 | 557 | 0 |
| 31 Dec 16 | 12,102 | 785 | 527 | 0 |
| 30 Sep 16 | 11,856 | 776 | 509 | 0 |
| 30 Jun 16 | 11,431 | 713 | 486 | 0 |
| 31 Mar 16 | 11,349 | 687 | 467 | 0 |
| 31 Dec 15 | 11,101 | 686 | 749 | 0 |
| 30 Sep 15 | 11,047 | 744 | 731 | 0 |
| 30 Jun 15 | 11,180 | 774 | 414 | 0 |
| 31 Mar 15 | 10,943 | 773 | 394 | 0 |
| 31 Dec 14 | 10,868 | 807 | 690 | 0 |
| 30 Sep 14 | 10,490 | 721 | 679 | 0 |
| 30 Jun 14 | 10,109 | 662 | 671 | 0 |
| 31 Mar 14 | 9,699 | 608 | 657 | 0 |
| 31 Dec 13 | 9,083 | 526 | 576 | 0 |
Kwaliteitswinsten: AARTIDRUGS has high quality earnings.
Groeiende winstmarge: AARTIDRUGS's current net profit margins (6.5%) are lower than last year (6.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: AARTIDRUGS's earnings have grown by 1.9% per year over the past 5 years.
Versnelling van de groei: AARTIDRUGS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: AARTIDRUGS had negative earnings growth (-12.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.2%).
Rendement op eigen vermogen
Hoge ROE: AARTIDRUGS's Return on Equity (12.2%) is considered low.